NFE2L2 and breast carcinoma: NRF2, considered a master regulator of cellular antioxidant response35, was identified as an upstream regulator of luminal-like hypoxia response (by IPA analysis), and stromal NRF2 protein expression by IHC was associated with high 33P in our breast cancer cohort.